Business angel Sergiu Negut exits Intermedicas, sells participation for EUR 40,000

Georgeta Gheorghe 05/09/2017 | 10:33

Business angel Sergiu Negut, exited Intermedicas, a company providing second-opinion services by selling his 15 percent participation to Iranian businessman Jabbar Kanani for EUR 40,000.

Intermedicas has been controlled since February by doctor Wargha Enayati, founder of private healthcare services provider Regina Maria.

Intermedica was founded in 2011 by neurologist Dan Mitrea, alongside Negut, who served as the company’s deputy director general, and Ana Maria Marian.

Inermedicas is the first healthcare company providing second opinion services and offers its clients access to services provided by international experts. Services include chiropractics and epileptology and are provided via 100 hospitals and clinics, including 15 private healthcare clinics in Romania, such as Regina Maria, MedLife, Ponderas and Monza, as well as state-own hospitals.

In 2016, the company posted a turnover of RON 1.3 million and RON 183,211 in losses. Businessman Kanani Jabbar heads Agricover, one of the biggest agribusiness players in Romania, with over 850 employees and around 4,500 clients at a national level. According to Forbes, Jabbar had an estimated fortune of EUR 30 million.

BR Magazine | Latest Issue

Download PDF or read online: March 2023 Issue | Business Review Magazine

The March 2023 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “25 Leaders to Watch in 2023.” Read it online by clicking here. To
Georgeta Gheorghe | 09/03/2023 | 17:26

    You will receive a download link for the latest issue of Business Review Magazine in PDF format, based on the completion of the form below.

    I agree with the Privacy policy of business-review.eu

    I agree with the storage and handling of my data by business-review.eu

    Advertisement Advertisement
    Close ×

    We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

    Accept & continue